The latest update keeps Coherus Oncology’s model fair value at US$6.75 per share, even as underlying assumptions around growth and risk have shifted. Some analysts who are more optimistic point to the ...

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and ...

A patented, generalized drug-response foundation model trained to internalize relationships between chemical structure, tumor biology, and therapeutic response, CertisAI™ enables zero-shot prediction ...

The integration supports treatment decisions across cancer care stages and helps reduce administrative tasks for clinicians.

Matthew Herper covers medical innovation — both its promise and its perils. Everything changed with a white envelope. On Dec.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel ...

Antibody drug conjugate programs (ADCs) are growing fast in oncology, combining selectivity with high potency.

The future of precision medicine will depend less on choosing between genomics or real-world evidence and more on how ...

The report offers comprehensive statistics, market size analysis, regional shares, and competitor insights. The oncology ...

Delivering value-based oncology care requires both scientific breakthroughs and deliberate system redesign, experts concurred ...

Myeloma delivery constraints are dominated by CAR T infrastructure and onboarding, while bispecifics are more ...

As a Houston high school senior, Dr. Ami Steinberg’s unexpected Hodgkin lymphoma diagnosis, which was discovered after a ...